DVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DaVita Inc (DVA) is not a strong buy for a beginner, long-term investor at this time. While the stock has shown some positive momentum in its technical indicators and has received favorable analyst upgrades, the lack of significant proprietary trading signals, hedge fund selling, and mixed options sentiment suggest caution. The investor may consider holding off on purchasing until a clearer entry point or stronger signals emerge.
The MACD is positive and contracting, indicating mild bullish momentum. RSI is neutral at 66.498, and moving averages are bullish with SMA_5 > SMA_20 > SMA_200. Key support and resistance levels are Pivot: 202.313, R1: 211.102, S1: 193.523, R2: 216.533, S2: 188.092. However, the stock has a 60% chance of declining slightly in the short term (-0.58% next day, -0.33% next week, -1.26% next month).
Analysts have raised price targets significantly following Q1 results, with UBS setting a high target of $235 and Deutsche Bank upgrading the stock to Buy with a $220 target. Earnings estimates have risen by 6.4%, and the company has shown strong performance in the kidney dialysis market.
Hedge funds are aggressively selling the stock, with a 6939.07% increase in selling activity over the last quarter. Options sentiment is bearish, and there is no recent congress trading data to indicate influential support. Additionally, the stock's short-term trend suggests potential for minor declines.
No financial data available for analysis due to an error in the provided data.
Analysts have raised price targets significantly, with UBS at $235, Deutsche Bank at $220, and others raising targets to $201-$205. However, most ratings remain Hold, with only a few Buy recommendations. This indicates mixed confidence in the stock's near-term performance.
